CVR 44515520Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)København NFounded 19 Dec 2023
Employees
2
CVR registry, Aug 2026
0 (0%) over 12 months
Revenue
579.9K
DKK, annual report 2025
+45% on 2024
Result
-502.7K
DKK, annual report 2025
Equity
-675.7K
DKK, annual report 2025
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about Polyceutix ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexPolyceutix Holding ApSCVR 44660318, 100% of capital and votes, since 14 Apr 2024
Mads Holmegaard Sørensensince 8 Sep 2026
Anton Allen Abbotsford Autzensince 19 Dec 2023
Equity was negative at 31 Dec 2025: -675.7K DKK. Dandex estimate, computed 26 Oct 2026.
CVR 44660318100% of capital and votessince 14 Apr 2024
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR 3964226333.3% to under 50% of capital and votes19 Dec 2023 to 14 Apr 2024
CVR 4382370166.7% to under 90% of capital and votes19 Dec 2023 to 14 Apr 2024
Ultimate controller
CVR 43823701Private limited company (ApS)
Holds 50% to under 66.7% of capital and votes in Polyceutix Holding ApS, since 22 Feb 2024
Holding company
CVR 44660318Private limited company (ApS)
Holds 100% of capital and votes in Polyceutix ApS, since 14 Apr 2024
This company
Polyceutix ApS
CVR 44515520
CVR records founders at incorporation. It does not record whether they are alive or still involved.
19 Dec 2023 to 26 Oct 2026.
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | 400 | 580 |
| Gross profit | 1,243 | 747 |
| Operating profit | -171 | -487 |
| Result for the year | -213 | -503 |
| Equity | -173 | -676 |
| Total assets | 4,394 | 4,331 |
| Employees (average) | 2 | 2 |
| Credit metrics (Dandex calculations) | ||
| Revenue growth (omsætningsvækst) | Not reportednote 1 | 45% |
| EBIT margin (overskudsgrad) | -42.9% | -84.1% |
| Employee growth (vækst i antal ansatte) | Not reportednote 1 | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | 2,162 | 4,288 |
| ROIC (afkast af investeret kapital) | Not reportednote 1 | -13.6%note 2 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | 2,157 | 3,853 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. No cash flow statement filed (class A and B are exempt).
Polyceutix ApS has new leadership, a good time to reach out.
Signal, a Dandex estimate. Lapses 17 Dec 2026.
Polyceutix ApS has changed ownership. A new strategy and new needs can be expected.
Signal, a Dandex estimate. Lapses 6 Jan 2027.
1 registered in CVR.
P-number 1029942567Ole Maaløes Vej 3, 2200 København N
